© 2023 Magellan Health, Inc. Polivy® (polatuzumab vedotin-piiq) (Intravenous) Document Number: IC-0482 Last Review Date: 05/04/2023 Date of Origin: 07/01/2019 Dates Reviewed: 07/2019, 09/2019, 07/2020, 12/2020, 07/2021, 07/2022, 05/2023 I. Length of Authorization 1,6 Cover...
Learn about POLIVY® (polatuzumab vedotin-piiq) plus R-CHP for adults with certain types of newly diagnosed diffuse large B-cell lymphoma (DLBCL). See full safety information.
Women of childbearing potential and men who are partners of such women should use effective contraception while receiving polatuzumab vedotin and for ≥3 months and ≥5 months, respectively, after the drug is discontinued.If used during pregnancy or if patient becomes pregnant, apprise of potential...
Tilly et al (2019; NCT01992653) stated polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, th...
Learn about POLIVY® (polatuzumab vedotin-piiq) in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with certain types of previously untreated diffuse large B-cell lymphoma
Polatuzumab vedotin Pregnancy WarningsUse is not recommended.AU TGA pregnancy category: DUS FDA pregnancy category: Not assigned. Risk Summary: Based on findings from animal studies and its mechanism of action this drug can cause fetal harm. Administration of the small molecule component of this ...
polatuzumab vedotin; however, those with the best survival outcomes had received fewer lines of prior treatment and were not considered refractory to their last line of treatment, supporting the idea that baseline characteristics can have an impact on the clinical outcome for some patient subgroups....
Polatuzumab vedotin dosing informationUsual Adult Dose for Lymphoma: 1.8 mg/kg IV every 21 days for 6 cycles in combination with bendamustine and rituximab; administer this drug, bendamustine, and rituximab in any order on Day 1 of each cycle-The recommended dose of bendamustine is 90 mg/m2/...